Jump to content
Powered by BIOPRO BW
  • BIOPRO BW
  • Healthcare industry
  • Project pages
    • MDR & IVDR
    • Innovation & Startups

Healthcare industry Logo

Main navigation

  • Start page Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close Close
  • Databases

    Databases

    Close Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 01/03/2022

    CureVac Establishes Fully-Owned Company Dedicated to Advancing The RNA Printer®

    The RNA Printer® is CureVac’s integrated and automated manufacturing solution for RNA vaccines and therapeutics. CureVac RNA Printer GmbH to provide dedicated infrastructure to accelerate development and broaden application range of The RNA Printer®. Dr. Markus Bergmann appointed as General Manager for CureVac RNA Printer GmbH.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-gruendet-tochtergesellschaft-zur-weiterentwicklung-des-rna-printer
  • Press release - 24/04/2023

    Hidden RNA repair mechanism discovered in humans

    Konstanz researchers discover the function of a previously unexplored protein: In three characteristic steps, "C12orf29" links the ends of RNA strands. Proteins that perform this kind of RNA ligation were previously unknown in humans. The results of the study suggest that it is important for RNA repair during cellular stress.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/hidden-rna-repair-mechanism-discovered-humans
  • Press release - 17/03/2025

    RNA Origami: Artificial Cytoskeletons to Build Synthetic Cells

    With the goal of creating living cells from non-living components, scientists in the field of synthetic biology work with RNA origami. This tool uses RNA biomolecule to fold new building blocks, making protein synthesis superfluous. In pursuit of the artificial cell, a research team has cleared a crucial hurdle. Using the new RNA origami technique, they succeeded in producing nanotubes that fold into cytoskeleton-like structures.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/rna-origami-artificial-cytoskeletons-build-synthetic-cells
  • Dossier - 02/12/2013 AI generated symbolic image of an RNA strand.

    RNA interference confidence is returning

    The 15-year history of RNA interference is not short on dramatic effects. It begins with the unexpected discovery and publication of the process of post-transcriptional gene silencing in 1998 for which Andrew Fire and Craig Mello were awarded the Nobel Prize in Physiology or Medicine just eight years after their discovery. In 2001 Thomas Tuschl succeeded in switching off genes in human cells with small synthetic pieces of RNA siRNA.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/rna-interference-confidence-is-returning
  • Article - 29/01/2019 RNA segments shown in black/grey, which are processed by grey and blue (represented as spheres) enzyme complexes.

    Targeted RNA editing with the body’s own enzyme activity

    Completely new possibilities for research and gene therapy became available following the development of the CRISPR/Cas method for targeted modification of the genome. However, treatment with molecular scissors is not without risk as potential errors are stored in the genome forever. Scientists from Tübingen have developed an alternative method in which the intervention takes place at the RNA level using the body's own enzymes and is thus…

    https://www.gesundheitsindustrie-bw.de/en/article/news/targeted-rna-editing-with-the-bodys-own-enzyme-activity
  • Press release - 29/06/2022

    RNA modifications in mitochondria promote invasive spread of cancer

    Mitochondria are the power plants of cells, and they contain their own genetic material and RNA molecules. Scientists from the German Cancer Research Center (DKFZ) have now discovered that certain modifications in mitochondrial RNA boost the invasive spread of cancer cells by supporting protein synthesis in mitochondria.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/rna-modifications-mitochondria-promote-invasive-spread-cancer
  • Article - 14/01/2021 Sven-Diederichs_Teaser.jpg

    Newly discovered RNA as growth driver in liver cancer

    Non-coding RNA (ncRNAs) molecules that do not encode proteins have many different functions, and some are associated with certain diseases. Prof. Dr. Sven Diederichs from the German Consortium for Translational Cancer Research and the German Cancer Research Center in Heidelberg has been conducting research into these molecules at the Freiburg University Medical Centre and discovered a ncRNA that regulates cell proliferation in cancer cells.

    https://www.gesundheitsindustrie-bw.de/en/article/news/newly-discovered-rna-growth-driver-liver-cancer
  • Vaccine development - 25/05/2021 AdobeStock_385688184_CROCOTHERY.jpg

    Vaccines - a beacon of hope in the fight against pandemics

    Having long been considered less lucrative for the big pharmaceutical companies, vaccine development is taking off in an unforeseen way in the wake of the COVID-19 pandemic. Financial support is flooding in and all kinds of vaccine development strategies are being deployed. Among the winners in the competition for effective coronavirus vaccines are vaccines based on RNA technology.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/vaccines-beacon-hope-fight-against-pandemics
  • Press release - 24/11/2022

    SARS-CoV-2 detection in 30 minutes using gene scissors

    Researchers of the University of Freiburg introduce biosensor for the nucleic acid amplification-free detection of SARS-CoV-2 RNA.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/sars-cov-2-nachweis-30-minuten-mit-der-genschere
  • Atriva Therapeutics - 21/10/2020 Kulturschalen mit blau angefärbten Zellen, zu denen das neue Coronavirus (SARS CoV-2) gegeben wurde. Die mit dem Wirkstoff ATR-002 von Atriva Therapeutics behandelten Zellen (rechte Reihen) zeigen keine weißen Löcher im Zellrasen und somit keine Zellzerstörung.

    COVID-19 pioneer drug in Phase II clinical trial - with double the power

    The effective treatment of people with severe COVID-19 is a major goal during the corona pandemic. ATR-002, an oral small molecule that targets RNA viruses such as influenza virus and SARS-CoV-2, has a dual effect: it impairs viral propagation and also has an immunomodulatory effect. And what’s more, due to its unique cellular mechanism of action, the efficacy of Atrivia Therapeutics’ drug candidate is not reduced by virus mutations and…

    https://www.gesundheitsindustrie-bw.de/en/article/news/covid-19-pioneer-drug-phase-ii-clinical-trial-double-power
  • Hummingbird Diagnostics GmbH - 22/09/2022 Logo-Hummingbird_Signet.jpg

    The great potential of blood-based microRNA analyses

    "The early bird catches the worm", is an apt description of what motivates Hummingbird Diagnostics GmbH from Heidelberg. The medium-sized biotechnology company analyses special biomarkers in blood, so-called microRNAs, in order to diagnose diseases at an early stage and to be able to make forecasts about the course of the disease and the success of therapy.

    https://www.gesundheitsindustrie-bw.de/en/article/news/great-potential-blood-based-microrna-analyses
  • Press release - 26/08/2024

    Synthetic Immunology: Approaching a Turning Point in the Treatment and Prevention of Disease

    Synthetic immunology is the topic of an article in the “Perspectives” section of the journal “Nature Nanotechnology”. Herein, Heidelberg researchers describe a so-called bottom-up approach that uses the toolbox of nanotechnology and synthetic biology to construct systems from molecular building blocks and specifically equip them with immune functions.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/synthetic-immunology-approaching-turning-point-treatment-and-prevention-disease
  • Press release - 07/02/2025

    Spliceosome: How cells avoid errors when manufacturing mRNA

    The spliceosome, ensures that the genetic information from the genome, after being transcribed into mRNA precursors, is correctly assembled into mature mRNA. Splicing is a basic requirement for producing proteins. Researchers at the Heidelberg University Biochemistry Center (BZH) have succeeded for the first time in depicting a faultily “blocked” spliceosome at high resolution and reconstructing how it is recognized and eliminated in the cell.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/spliceosome-how-cells-avoid-errors-when-manufacturing-mrna
  • Dossier - 28/04/2014 Researcher sitting in front of two screens, visualising a protein on the screen using a specific software.<br />

    Data mining new opportunities for medicine and public health

    Research and healthcare activities produce huge quantities of data that need to be presented in an understandable structure. This requires computer-assisted extraction of relevant data and the use of statistical methods. This process, known as data mining, enables the discovery of patterns in large data sets. Data mining methods are of particular importance in fields that use high-throughput, visualisation methods and telemedical applications.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/data-mining-new-opportunities-for-medicine-and-public-health
  • PixelBiotech GmbH - 27/07/2021 Teaser_HuluFISH_7_color_med.jpg

    Searching for tracks with cytogenetics and AI

    The startup Pixelbiotech combines fluorescence techniques with artificial intelligence to detect DNA and RNA in medical samples. HuluFISH is the name of the method, which allows for countless applications - from detecting viral infections, such as COVID-19 or African swine fever virus, to the quality control of gene and immunotherapeutic procedures in cancer medicine.

    https://www.gesundheitsindustrie-bw.de/en/article/news/searching-tracks-cytogenetics-and-ai
  • Press release - 03/06/2022

    Deep Learning helps improve gene therapies and antiviral drugs

    The nuclease Cas13b associated with the CRISPR gene scissors, which is an enzyme that degrades nucleic acids, has the potential to be used in the future in hereditary diseases to switch off unwanted genes. In the fight against infections, this nuclease is also being researched as an antiviral agent, as Cas13b can specifically intervene in the genetic material of viruses and render them harmless.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/deep-learning-helps-improve-gene-therapies-and-antiviral-drugs
  • Press release - 28/03/2025

    Quality Assurance in the Cell: Preventing Defective Protein Blueprints

    Two molecular control factors play a decisive role in what is known as splicing, the cutting and assembly of mature messenger RNA – a prerequisite for protein synthesis in the cell. The poorly characterized factors are crucial to ensuring that the molecular machine responsible for splicing is working correctly. A research team has deciphered how the two cellular quality inspectors work.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/quality-assurance-cell-preventing-defective-protein-blueprints
  • Dossier - 06/12/2019 Staphylococcus-lugdunensis-Antibiotikum.jpg

    Microbiome: human health is closely connected with our microbial communities

    People have 1.3 times more microorganisms than body cells. This microbial community influences how we digest our food, how active our immune system is, as well as whether we tend to be more anxious or curious. A number of diseases have also been shown to be associated with a disturbed microbiome. Researchers still have a long way to go before the knowledge acquired can be used for developing therapies.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/microbiome-human-health-closely-connected-with-microbial-communities
  • Press release - 16/07/2021

    Corona test with cotton swab

    To diagnose an infection with the coronavirus, usually a throat swab is taken and genetic viral material detected by using a highly sensitive PCR. To date, more than 65 million of these tests have been performed in Germany alone. Due to the massive increase in testing worldwide and simultaneous loss of production, there was a significant shortage of test materials in the early stage of the pandemic.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/corona-test-cotton-swab
  • Press release - 16/08/2021

    Blood-based micro-RNAs indicate the risk of colorectal cancer

    The risk of colorectal cancer can be predicted more accurately by determining seven blood-based micro-RNAs (miRNAs) than by using traditional methods - and can be done so many years before a diagnosis is made. In a current study, researchers from the German Cancer Research Center and the National Center for Tumor Diseases (NCT) Heidelberg show that miRNA profiles provide greater predictive accuracy than genetic or lifestyle-based risk…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/blood-based-micro-rnas-indicate-risk-colorectal-cancer
  • Vaccine development - 02/06/2020 07777_de.jpg

    CureVac as a pioneer of mRNA technology - what is behind the novel COVID-19 vaccine?

    All eyes are on vaccines against the coronavirus. The Tübingen-based company CureVac is doing pioneering work in this field, and intends to initiate clinical testing of its lead vaccine candidate in June. At the same time, Curevac is manufacturing the material for this vaccine candidate. But that’s not all: the novel mRNA technology also has the potential to revolutionise the treatment of cancer and metabolic diseases. What makes the method so…

    https://www.gesundheitsindustrie-bw.de/en/article/news/curevac-als-pionier-der-mrna-technologie-was-steckt-hinter-dem-neuartigen-covid-19-impfstoff
  • Press release - 22/08/2024

    Validated targets for personalized cancer immunotherapy

    Knowledge of the target structures for the immune cells is a basic prerequisite for the development of personalized cancer immunotherapies. Scientists from the German Cancer Research Center and the NCT Heidelberg are publishing a sensitive method based on mass spectroscopy to identify such tumor-specific "neoepitopes". The analytical method is designed to detect these low abundance protein fragments and requires minimal amounts of…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/validated-targets-personalized-cancer-immunotherapy
  • Press release - 05/07/2024

    Outstanding ideas – new imaging processes for cancer diagnostics and nanopropellers for ocular gene therapy

    The summer reception hosted by BioRegio STERN Management GmbH has once again provided a fitting backdrop for the Science2Start award ceremony. Last Thursday, at Tübingen observatory, was the 15th time that scientists and start-up founders were celebrated for outstanding ideas that a panel of experts judged to have special economic potential.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/outstanding-ideas-new-imaging-processes-cancer-diagnostics-and-nanopropellers-ocular-gene-therapy
  • Press release - 21/09/2022

    ERC funding: How to deliver gene therapies to a specific target site?

    With its "Proof of Concept" grants, the European Research Council ERC supports scientists in further developing the commercial potential of their research results. Nina Papavasiliou from the DKFZ is now receiving the prestigious grant for the second time: she wants to advance the development of a "molecular delivery service" that ensures that therapeutic genes reach the right address in the body in a targeted manner.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/erc-funding-how-deliver-gene-therapies-specific-target-site
  • Press release - 29/11/2021

    Tracking down resistant cancer cells

    In multiple myeloma, a cancer of the bone marrow, relapse almost always occurs after treatment. Initially, most patients respond well to therapy. However, as the disease progresses, resistant cancer cells spread in the bone marrow, with fatal consequences for the patients.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/tracking-down-resistant-cancer-cells
  • Gene regulation as a starting point for cancer therapies - 02/12/2021 Schematische Darstellung der verschiedenen Stadien der Genexpression. Nukleinsäurestränge sind durch farbige Linien, Proteine durch farbige Ellipsen und die Methylierung durch kleine Kreise dargestellt.

    New investigation method for deciphering complex epigenetic networks

    The development and maintenance of uncontrolled cell division in tumours is often due to the unbalanced, complex interplay of regulatory epigenetic networks. Researchers at the Institute of Biochemistry and Technical Biochemistry in Stuttgart have developed a new screening system to identify essential components that can serve as targets for anticancer drugs.

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-investigation-method-deciphering-complex-epigenetic-networks
  • Dossier - 10/11/2014 22065_de.jpg

    Cell and gene therapies from bench to bedside

    While cell therapy has become standard treatment for a number of blood cancers, most cell and gene therapy approaches for the treatment of hereditary and metabolic diseases, neurodegenerative disorders and cancer are still in the experimental phases or early clinical trials. However, recent successes give rise to the hope that cell and gene therapies will in future make important contributions to previously incurable diseases.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/cell-and-gene-therapies-from-bench-to-bedside
  • Press release - 13/06/2024

    Which of the two DNA strands is damaged influences the cell's mutation profile

    Cancer genomes are the result of diverse mutation processes. Scientists have analyzed the molecular evolution of tumors after exposure to mutagenic chemicals. DNA lesions that persists unrepaired over several cell generations lead to sequence variations at the site of damage. This enabled the researchers to distinguish the contribution of the triggering lesion from that of the subsequent repair in shaping the mutation pattern.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/which-two-dna-strands-damaged-influences-cells-mutation-profile
  • Press release - 14/01/2025

    Epigenetics ensures placenta functioning

    If the development of blood vessels in the placenta is impaired, fetal growth retardation may result. Scientists from the German Cancer Research Center (DKFZ) and the Mannheim Medical Faculty of Heidelberg University discovered that the correct development of functioning blood vessels in the mouse placenta is controlled epigenetically: One of the enzymes that modify gene activity using methyl groups is responsible.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/epigenetics-ensures-placenta-functioning
  • Press release - 20/06/2023

    CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma

    CureVac N.V. today announced that it has dosed the first patient with its investigational cancer vaccine CVGBM in a Phase 1 study. CVGBM is based on CureVac’s proprietary second-generation mRNA backbone and features a single mRNA, encoding eight epitopes derived from known tumor-associated antigens with demon­strated relevance in glioblastoma. A first data readout is expected in the second half of 2024.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-doses-first-patient-phase-1-study-cancer-vaccine-candidate-surgically-resected-glioblastoma
  • Article - 22/03/2019 Prof. Lichter (left) and Prof. Schneeweiss, who run the Translational Breast Cancer Programme in Heidelberg, in the laboratory

    Personalised therapies for treating metastasing breast cancer

    Breast cancer is characterised by broad genetic diversity. Successful treatment is made even more difficult by the fact that, in advanced breast cancer, the properties of metastases often differ significantly from the primary tumour. The Heidelberg CATCH study is now collecting genetic profiles from patients' metastasis tissue samples, which can be used to tailor therapy to individual requirements.

    https://www.gesundheitsindustrie-bw.de/en/article/news/personalisierte-therapieansaetze-bei-metastasiertem-brustkrebs
  • Dossier - 01/04/2013 19423_de.jpg

    Retroviruses from infectious agent to therapeutic assistant

    Viruses are infectious particles that use the machinery and metabolism of a host cell to replicate. The family of retroviruses is particularly known for its most notorious representative i. e. the human immunodeficiency virus HIV. However retroviruses are not only of interest for researchers looking for effective cures for viral infections their characteristic properties also make them promising laboratory and gene therapy tools.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/retroviruses-from-infectious-agent-to-therapeutic-assistant
  • Press release - 25/10/2023

    Epigenetically acting drugs could support cancer immunotherapy

    Epigenetically active drugs enable the cell to read parts of the genome that were previously blocked and inaccessible. This leads to the formation of new mRNA transcripts and also new proteins, as scientists from the German Cancer Research Center and the University Hospital Tübingen have now published. These "therapy-induced epitopes" could help the immune system recognize cancer cells.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/epigenetically-acting-drugs-could-support-cancer-immunotherapy
  • Press release - 25/10/2023

    Epigenetically acting drugs could support cancer immunotherapy

    Epigenetically active drugs enable the cell to read parts of the genome that were previously blocked and inaccessible. This leads to the formation of new mRNA transcripts and also new proteins, as scientists from the German Cancer Research Center and the University Hospital Tübingen have now published. These "therapy-induced epitopes" could help the immune system recognize cancer cells.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/epigenetisch-wirkende-medikamente-koennten-krebs-immuntherapie-unterstuetzen
  • microRNA as a prognostic biomarker - 13/01/2022 Screen of an ECG device showing the typical action potentials of the heart muscle.

    Heart attack diagnosis: fast and unambiguous thanks to artificial intelligence

    People that arrive in emergency rooms with chest pain require swift action in order to rule out a heart attack or to initiate vital life-saving therapy. However, despite many advances, current tests are not yet optimal: they either take hours or produce false-positive results. Researchers at Heidelberg University Hospital are now using AI in an approach that takes microRNAs from a blood sample to specifically diagnose ‘acute coronary syndrome’.

    https://www.gesundheitsindustrie-bw.de/en/article/news/heart-attack-diagnosis-fast-and-unambiguous-thanks-artificial-intelligence
  • Press release - 04/03/2021

    Induced pluripotent stem cells reveal causes of disease

    Induced pluripotent stem cells (iPSC) are suitable for discovering the genes that underly complex and also rare genetic diseases. Scientists from the German Cancer Research Center (DKFZ) and the European Molecular Biology Laboratory (EMBL), together with international partners, have studied genotype-phenotype relationships in iPSCs using data from approximately one thousand donors.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/induced-pluripotent-stem-cells-reveal-causes-disease
  • Press release - 10/01/2022

    Algorithm identifies cancer drivers

    Genetic alterations that promote the development and spread of tumors are difficult to identify. This is especially true for mutations in the non-protein-coding regions of the genome, which include all important regulatory sequences. Scientists at the German Cancer Research Center have now published an algorithm that detects cancer drivers in both the protein-coding and non-coding regions of the genome.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/algorithm-identifies-cancer-drivers
  • Press release - 18/10/2023

    SARS-CoV-2: Alert immune system in the respiratory tract protects children from severe courses of the disease

    Why are severe courses of SARS-CoV-2 infection less common in children and adolescents than in adults? Scientists at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have now discovered that the immune system in the upper respiratory tract is much more alert and active in children before infection than in adults and is therefore better equipped to fight the virus.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/sars-cov-2-aktiveres-immunsystem-den-atemwegen-schuetzt-kinder-vor-schweren-verlaeufen
  • Press release - 17/04/2024

    Cell Biology: Molecular Code Stimulates Pioneer Cells to Build Blood Vessels in the Body

    Cardiovascular diseases, including stroke and myocardial infarction, are the world's leading causes of mortality, accounting for over 18 million deaths a year. A team of KIT researchers has now identified a new cell type in blood vessels responsible for vascular growth. This discovery may allow for novel therapeutic strategies to treat ischemic cardiovascular diseases, i.e. diseases that are caused by reduced or absent blood flow.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/zellbiologie-molekularer-code-regt-pionierzellen-zum-aufbau-von-blutgefaessen-im-koerper
  • Press release - 16/01/2025

    New weapons against viruses

    Dr. Petr Chlanda, virologist and research group leader at the Heidelberg Medical Faculty of Heidelberg University, has been awarded more than 720,000 euros in funding from the European Union for his research into new therapies against viruses. His work is part of the interdisciplinary, international DEFENDER project, which is developing innovative approaches to combat emerging and re-emerging viruses.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-weapons-against-viruses
  • Chronic inflammatory bowel diseases - 25/09/2024 Vor schwarzem Hintergrund sind kugelförmige Zellansammlungen zu sehen.

    Proinflammatory regulatory T lymphocytes as a therapeutic target in Crohn's disease

    Chronic inflammatory bowel diseases are very stressful for those affected and increase the risk of bowel cancer. PD Dr. Robyn Laura Kosinsky from the Bosch Health Campus in Stuttgart, together with researchers from the USA, identified disfunctional regulatory T cells as important drivers of inflammation in Crohn's disease. They also found that with the help of an epigenetically active drug, it was possible to restore the cells’ original…

    https://www.gesundheitsindustrie-bw.de/en/article/news/proinflammatory-regulatory-t-lymphocytes-therapeutic-target-crohns-disease
  • Viral zoonoses - 24/01/2022 Schematic drawing of a flavivirus polyprotein anchored in the ER membrane. The different viral proteins are indicated by differently coloured sections on the polyprotein that is marked with dashes and the protease interfaces are marked by arrows.

    Development of inhibitors that help stop viral zoonoses

    Emerging viral infections such as COVID-19 or Zika disease pose an increasing threat to humans. At the Institute of Pharmacy and Molecular Biotechnology (IPMB) at Heidelberg University, Prof. Dr. Christian Klein's research group is developing inhibitors against already known viruses in the hope that these can also be used against new virus variants.

    https://www.gesundheitsindustrie-bw.de/en/article/news/development-inhibitors-help-stop-viral-zoonoses
  • Press release - 06/01/2023

    CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs

    CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced positive preliminary data from ongoing Phase 1 clinical programs in COVID-19 and seasonal flu, assessing both modified and unmodified mRNA technology. The tested vaccine candidates are being developed in collaboration with GSK.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-announces-positive-data-joint-covid-19-and-flu-mrna-vaccine-development-programs
  • Gene regulation - 20/07/2021 Vor schwarzem Hintergrund ist ein gelb leuchtendes Chromosom zwischen blau gefärbten Chromosomen sichtbar.

    The many faces of the epigenetic regulator MOF

    Epigenetic modifications play a crucial role in coordinated gene transcription, and are required for a fertilised egg cell to be able to develop into an organism with different cell types. Dr. Asifa Akhtar from the Max Planck Institute of Immunobiology and Epigenetics in Freiburg has been studying the essential epigenetic regulator protein MOF for 20 years.

    https://www.gesundheitsindustrie-bw.de/en/article/news/die-vielen-gesichter-des-epigenetischen-regulators-mof
  • Press release - 25/05/2021

    How “paralyzed” immune cells can be reactivated against brain tumors

    Brain tumor cells with a certain common mutation reprogram invading immune cells. This leads to the paralysis of the body's immune defense against the tumor in the brain. Researchers from Heidelberg, Mannheim, and Freiburg discovered this mechanism and at the same time identified a way of reactivating the paralyzed immune system to fight the tumor.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-paralyzed-immune-cells-can-be-reactivated-against-brain-tumors
  • Press release - 30/10/2024

    Diabetes switch in DNA: Non-coding region in the genome influences ONECUT1 gene

    They are underestimated genetic control elements: it is known that changes in the genome can trigger diabetes. But now researchers at the University Hospital Ulm and the INSERM Cochin Institute in Paris have shown that a previously under-researched region of the genome also plays a crucial role in the development of this disease.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/diabetes-switch-dna-non-coding-region-genome-influences-onecut1-gene
  • Trenzyme GmbH - 20/05/2020 Coronavirus im Elektronenmikroskop

    The SARS-CoV spike protein and its receptor

    The SARS-CoV-2 coronavirus uses a spike protein to bind to the ACE2 receptor on the cell surfaces of lung tissue. Additional cofactors are needed to allow the virus genome to penetrate human cells and multiply. Knowing these relationships can help understand the course of the infection and develop counterstrategies. To this end, the Constance-based company Trenzyme has produced a recombinant spike protein to support coronavirus research.

    https://www.gesundheitsindustrie-bw.de/en/article/news/the-sars-cov-spike-protein-and-its-receptor
  • Bioinspired technologies - 03/04/2020 Foto vom Biosensor in Brauntönen; darauf eingezeichnet sind die elektrochemischen Funktionsprinzipien mit Strukturformeln.

    Diagnostics with molecular scissors – is this also possible for on-site COVID-19 tests?

    The CRISPR-Cas gene-editing technology is one of the most important developments in molecular biology in recent years. It utilises molecular scissors with which nucleic acids can be cut and edited almost arbitrarily. Researchers in Freiburg, Germany have now successfully used the technology for diagnostic purposes. They are currently working intensively on expanding the system to enable it to detect genome sequences of the novel SARS-CoV-2 virus.

    https://www.gesundheitsindustrie-bw.de/en/article/news/Diagnostics-with-molecular-scissors-is-this-also-possible-for-on-site-COVID-19-tests
  • Dossier - 12/03/2012 One hand holds a cell culture plate with six different cell cultures

    Regenerative medicine makes use of patients own resources

    Die Regenerative Medizin bietet neue Therapieoptionen quer durch die ärztlichen Fachgebiete. Zumeist sind es zellbasierte Verfahren und sie werden häufig mit innovativen Biomaterialien kombiniert. Regenerative Therapien vereinen Know-how aus den Biowissenschaften mit moderner Medizintechnik und sie profitieren von den Fortschritten in den Ingenieur- und Materialwissenschaften.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/regenerative-medicine-makes-use-of-patients-own-resources
  • Press release - 09/11/2022

    New Molecular Microscopy Uncovers how Breast Cancer Spreads

    Researchers have created a tool that maps how breast cancer grows in previously unseen detail, and highlights how the cells around the tumour may be the key to controlling the spread of disease. The new technology can trace which populations of breast cancer cells are responsible for the spread of the disease, and for the first time highlights how the location of cancer cells could be as important as mutations in tumor growth The new study is…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-molecular-microscopy-uncovers-how-breast-cancer-spreads
  • Overview

    Basic research

    https://www.gesundheitsindustrie-bw.de/en/article/research
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
  • Portals
    • BIOPRO BW
    • Healthcare industry
  • To top

stay informed

Newsletter abonnieren

Social Media

  • Xing Xing
  • Twitter visit Twitter
  • LinkedIn visit LinkedIn
  • Rss visit RSS
  • Privacy statement
  • Accessability Declaration
  • Legal notice
  • Sitemap
  • Contact
© 2025
Website address: https://www.gesundheitsindustrie-bw.de/en/search